Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
enadenotucirev · 1 trial · 3 indications
Review of adverse events including serious adverse events (SAEs), adverse events meeting protocol defined DLT criteria, adverse events leading to study treatment or study discontinuation, and adverse events resulting in death
Maximum tolerated dose (MTD) / maximum feasible dose (MFD) of enadenotucirev administered IV in combination with nivolumab.
| Arm | Type | Description |
|---|---|---|
| enadenotucirev and nivolumab | EXPERIMENTAL | - |
| Name | Type | Description |
|---|---|---|
| enadenotucirev | BIOLOGICAL | - |
| nivolumab | BIOLOGICAL | - |
Inclusion Criteria: * Adult males or females aged 18 years or over * Disease status: - Diagnosis of metastatic or advanced CRC, UCC, SCCHN, salivary gland cancer or NSCLC not responding to standard therapy or for whom no standard treatment exists * For patients who have received prior PD-1 / PD-L1 ...
Top 20 of 77 competitors
Enadenotucirev is an investigational monoclonal antibody being studied for the treatment of colorectal cancer. It is also being evaluated in patients with squamous cell carcinoma of the head and neck and other epithelial tumors. The drug is currently in Phase 1 clinical development.
Enadenotucirev is being developed by Bristol-Myers Squibb Company, which trades on the New York Stock Exchange under the ticker symbol BMY. The company is conducting clinical trials to evaluate the drug's safety and efficacy in patients with advanced epithelial tumors.
Enadenotucirev is in Phase 1 clinical development. It is an investigational drug and has not been approved by regulatory authorities. A Phase 1 study of enadenotucirev in combination with a PD-1 inhibitor has been completed in patients with metastatic or advanced epithelial tumors.
Enadenotucirev has been studied in one clinical trial with the identifier NCT02636036. This Phase 1 study evaluated enadenotucirev in combination with a PD-1 inhibitor in subjects with metastatic or advanced epithelial tumors, including colorectal cancer and squamous cell carcinoma of the head and neck. The trial enrolled 51 participants in the United States.
Enadenotucirev is a monoclonal antibody, but its specific molecular target has not been disclosed in available information. It is being studied in combination with a PD-1 inhibitor, suggesting it may modulate immune responses, though the exact mechanism of action remains under investigation.